Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Hypertension 2Diabetes Mellitus, Type 2 2Cushing Syndrome 2ACTH Syndrome, Ectopic 2Pituitary ACTH Hypersecretion 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Carboplatin 8Paclitaxel 7Hyperthermic Intraperitoneal Chemotherapy 7Bevacizumab 4liposomal doxorubicin 3Gemcitabine 3Oxaliplatin 2Neoadjuvant Therapy 2relacorilant 1phenoxodiol 1pembrolizumab 1oregovomab 1olaparib 1nintedanib 1lobaplatin 1lanreotide 1epothilone B 1atezolizumab 1Trabectedin 1Topotecan 1Therapeutics 1Surgical Procedures, Operative 1Saline Solution 1Leucovorin 1Letrozole 1Laparotomy 1Laparoscopy 1LAIF 900 1Hypericum extract LI 160 1Glucose 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Peritoneal Neoplasms × relacorilant × Clear all
NCT05257408 2025-04-16

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Corcept Therapeutics

Phase 3 Active not recruiting
381 enrolled 1 FDA
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡